Method of manufacturing an implantable device

• US 9,072,786 B2
• Filed: 05/20/2013
• Issued: 07/07/2015
• Est. Priority Date: 06/25/2008
• Status: Active Grant

• Current Assignee: Endo Pharmaceuticals Solutions Incorporated (Endo International PLC)
• Original Assignee: Endo Pharmaceuticals Solutions Incorporated (Endo International PLC)
• Inventors: Kuzma, Petr, Decker, Stefanie, Quandt, Harry
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US13/897,895
• Publication Number:
  US 20130252894A1
• Time in Patent Office: 778 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/22 Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/40 Cyclodextrins; Derivatives thereof
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/08 for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.

Claims

1. A method of manufacturing an implantable device, wherein the implantable device can deliver a therapeutic polypeptide agent to a subject, and the release of the therapeutic polypeptide agent from the implantable device can be modulated by varying the components or the amounts of the components of the implantable device, the method comprising:

a) mixing one or more polymerizable monomeric substances;

b) adding one or more substances selected from the group consisting of;

an excipient, a wetting agent, a non-ionic surfactant, an organic solvent, an alcohol, a reducing agent, an oxidizing agent and an aqueous solvent; and

c) subjecting the mixture to conditions that cause the one or more polymerizable monomeric substances to polymerize in the presence of the one or more components, thereby forming the implantable device, wherein the mixture comprises a mixture selected from the group consisting of;

a) about 78.72% HEMA (hydroxyethyl methacrylate), about 0.40% EGDMA (ethyleneglycol dimethacrylate), about 0.79% Vitamin E TDGS, about 0.24% BME (benzoin methyl ether), about 0.08% P-16 (Parkadox®

     16), about 9.89% water and about 9.89% isopropyl alcohol;

b) about 78.72% HEMA, about 0.40% EGDMA, about 0.79% Vitamin E TDGS, about 0.24% BME, about 0.08% P-16 and about 19.78% water;

c) about 68.97% HEMA, about 0.35% EGDMA, about 0.69% Vitamin E TDGS, about 0.21% BME, about 0.07% P-16, about 14.85% water and about 14.85% isopropyl alcohol; and

d) about 68.97% HEMA, about 0.35% EGDMA, about 0.69% Vitamin E TDGS, about 0.21% BME, about 0.0796 P-16 and about 29.71%.

2. The method of claim 1, wherein the rate of release of the therapeutic polypeptide can be modulated.

3. The method of claim 1, wherein the mixture is placed into a mold prior to being subjected to a polymerization step.

4. The method of claim 3, wherein the polymerization step is initiated by ultraviolet irradiation.

5. The method of claim 1, further comprising charging the implantable device with a desired amount of a therapeutic polypeptide agent.

6. The method of claim 5, wherein the therapeutic polypeptide agent comprises a GLP-1 analog.

7. The method of claim 6, wherein the GLP-1 analog comprises exenatide.

8. The method of claim 1, wherein the therapeutic polypeptide agent is combined with a wetting agent to form a solid formulation prior to being charged into the implantable device.

9. The method of claim 8, wherein the solid formulation comprises about 98% exenatide and about 2% stearic acid.